Under the title, What’s Next in Psoriasis? From Maintenance to Disease Modification, the 2022 IPC Think Tank scientific symposium was held on Friday, December 9th, in Miami, Florida. Read the full report or a summary of the five psoriasis focused sessions.
The IPC’s global network of experts generously volunteers their time every year to educate and train other physicians to better care for people with psoriasis. We would like to recognize our top three Councilors that went above and beyond in 2022 to support our work.
The patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is making it a priority.
La investigación de la Dra. Kelly Cordoro sobre la psoriasis pediátrica muestra que puede ser hora de repensar nuestras expectativas sobre las comorbilidades y el tratamiento.
Dr. Kelly Cordoro’s research on pediatric psoriasis shows it may be time to rethink our expectations about comorbidities and treatment.
In 2022, the IPC advanced in the worldwide psoriasis community, ranging from multiple research efforts, education of dermatologists, and public awareness, reaching the patient communities. In addition to face-to-face events, the IPC has expanded its digital presence. Read some of IPC’s significant achievements from the past year and leave a comment letting us know what topics you want to see on the IPC website in the coming year!
El Proyecto de Reclasificación de la Severidad de la Psoriasis de los Consejos Internacionales de Psoriasis tiene como objetivo cambiar la clasificación de la gravedad de la psoriasis. La red de líderes de opinión clave del IPC acordó una definición para cada categoría de gravedad de la enfermedad.
O Projeto de Reclassificação da Gravidade da Psoríase do Conselho Internacional de Psoríase visa alterar a classificação da gravidade da psoríase. A rede de líderes de opinião do IPC concordou com uma definição para cada categoria de gravidade da doença.
International Psoriasis Councils’ Psoriasis Severity Reclassification Project aims to change the classification of psoriasis severity. IPC’s network of key opinion leaders agreed on a definition for each category of disease severity.
European Commission grants conditional marketing authorization based on the EFFISAYIL® 1 trial, which showed over half of the spesolimab-treated patients were free of pustules, one week after receiving a single dose. This decision builds on existing approvals in the United States and Japan.